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CFP32 is a Mycobacterium tuberculosis complex-
restricted secreted protein that was previously reported to
be present in a majority of sputum samples from patients
with active tuberculosis (TB) and to stimulate serum
antibody production. CFP32 (annotated as Rv0577) was
therefore considered a good candidate target antigen for the
rapid serodiagnosis of TB. However, the maximal sensitivity
of CFP32 serorecognition may have been limited in earlier
studies because recombinant CFP32 (rCFP32) produced in
Escherichia coli was used as the test antibody-capture anti-
gen, a potential shortcoming stemming from differences
in bacterial protein posttranslational modiﬁcations. To
further investigate the serodiagnostic potential of rCFP32
synthesized in different heterologous hosts, we expressed
rCFP32 in the yeast Pichia pastoris. Compared to E. coli
rCFP32, yeast rCFP32 showed a higher capacity to capture
polyclonal antisera in Western blot studies. Likewise, yeast
rCFP32 was signiﬁcantly better recognized by sera from TB
patients, in enzyme-linked immunosorbent assay (ELISA),
than E. coli rCFP32. In subsequent testing, the yeast
rCFP32-based antibody-capture ELISA had a sensitivity of
85% and a speciﬁcity of 98% for the discrimination of active
TB cases (n = 40) from BCG vaccinees (n = 39). The sensitivity
was surprisingly high for a single-antigen TB serodiagnostic
test compared to tests using E. coli-expressed antigens.
Overall, the trans-production of rCFP32 in P. pastoris signif-
icantly improved the serologic detection of CFP32-speciﬁc
antibodies in patient sera, thereby offering a new, possibly
better, modality for producing antigens of diagnostic
potential for use in the development of immunoassays for
both TB and other infectious diseases (International patent
request CA 2,551,537 of July 3rd, 2007).
doi:10.1016/j.ijid.2008.05.1326
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One year experience of APTIMA COMBO 2 Transcription
Mediated Assay (TMA) for detection of Chlamydia tra-
chomatis and Neisseria gonorrhoea in a large private
pathology laboratory in Queensland
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Between June 2005 and July 2006, a total of 90898 sam-
ples including urine and non urine specimens were processed
using the Aptima Combo 2 Assay (AC2) which has the abil-
ity to detect both Chlamydia trachomatis (CT) and Neisseria
gonorrhoea (GC) in the same sample
Results: Overall CT was detected in 6.8% of samples. CT
was detected in 7.8% of urine specimens and 5.3% of geni-
tal specimens. CT was also detected in 69 tampon samples
(12%), 34 Thin Prep samples (3.2%), 30 eye swabs (5.2%), 30
rectal swabs (8.7%), 14 throat swabs (1.4%) and 1 seminal
ﬂuid (1.1%).
Overall GC was detected in 0.7% of samples. GC was
detected in 0.6% of urines specimens and 0.45% of genital
swabs. GC was detected in 50 throat swabs (5.1%), 41 rectal
swabs (12%), 11 tampons (1.9%) and 3 eye swabs (0.5%). Dual
infections with CT and GC were detected in 0.7% of all sam-
ples. Overall prevalence of GC by culture was 0.3%. None
had a positive GC culture and a negative AC2 assay result.
21% of specimens positive for GC by AC2 did not have a for-
mal request for GC by AC2 (GCNR: GC Not Requested). 29%
GCNR GC positive specimens by AC2 did not have a simulta-
neous culture request. 18% GCNR GC positive specimen had
concurrent CT infection
Conclusions: CT and GC were detected by AC2 assay in a
wide range of sample types. AC2 was more sensitive than
culture for detection of GC. The ability of the assay to
detect both CT and GC in one sample has emphasised the
importance of testing for dual infections and enabled the
un-requested GC to be detected. The data suggests that clin-
icians are opting for molecular- based testing for GC rather
than culture- based methods.
doi:10.1016/j.ijid.2008.05.1327
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Introduction: Ornithobacterium rhinotracheale (ORT) is
a pleomorphic gram-negative Rod-shaped bacterium that
has been isolated from chickens manifesting severe respira-
tory problems in many countries. ORT can be associated with
high economic losses in poultry. Only 10 to 15% of Escherichia
coli (E. Coli) intestinal coliforms are pathogenic (APEC). The
aims of this study were the isolation of Ornithobacterium
rhinotracheale and Escherichia coli from poultry and iden-
tiﬁcation of the isolates by Polymerase chain reaction (PCR)
for ORT and serology for E. Coli.
Materials: Samples. In this study Samples collected from
lung and trachea from 13 commercially chicken ﬂocks show-
ing respiratory disease symptoms were pooled, homogenized
and stored at -80 ◦C until required.
Bacteriology.
ORT: Samples were aseptically inoculated on blood agar
supplemented with 7% sheep blood and 10g/ml gentamicin
(to inhibit growth of other bacteria) to isolate and iden-
tify the causative bacteria from lung and trachea samples
by routine both culture and PCR. The plates were incu-
